AMP‐activated protein kinase mediates glucocorticoid‐ induced metabolic changes: a novel mechanism in Cushing's syndrome
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Chronic exposure to glucocorticoid hormones, resulting from either drug treatment or Cushing's syndrome, results in insulin resistance, central obesity, and symptoms similar to the metabolic syndrome. We hypothesized that the major metabolic effects of corticosteroids are mediated by changes in the key metabolic enzyme adenosine monophosphate‐activated protein kinase (AMPK) activity. Activation of AMPK is known to stimulate appetite in the hypothalamus and stimulate catabolic processes in the periphery. We assessed AMPK activity and the expression of several metabolic enzymes in the hypothalamus, liver, adipose tissue, and heart of a rat glucocorticoid‐excess model as well as in in vitro studies using primary human adipose and primary rat hypothalamic cell cultures, and a human hepatoma cell line treated with dexamethasone and metformin. Glucocorticoid treatment inhibited AMPK activity in rat adipose tissue and heart, while stimulating it in the liver and hypothalamus. Similar data were observed in vitro in the primary adipose and hypothalamic cells and in the liver cell line. Metformin, a known AMPK regulator, prevented the corticosteroidinduced effects on AMPK in human adipocytes and rat hypothalamic neurons. Our data suggest that glucocorticoid‐induced changes in AMPK constitute a novel mechanism that could explain the increase in appetite, the deposition of lipids in visceral adipose and hepatic tissue, as well as the cardiac changes that are all characteristic of glucocorticoid excess. Our data suggest that metformin treatment could be effective in preventing the metabolic complications of chronic glucocorticoid excess.— Christ‐Crain M., Kola, B., Lolli F., Fekete, C., Seboek, D., Wittmann, G., Feltrin, D., Igreja, S. C., Ajodha, S., Harvey‐White, J., Kunos, G., Müller B., Pralong, F., Aubert, G., Arnaldi, G., Giacchetti, G., Boscaro, M., Grossman, A. B., Korbonits M. AMP‐activated protein kinase mediates glucocorticoidinduced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 22, 1672–1683 (2008)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“The ability of metformin to lower blood glucose requires LKB1 and AMPK signals (48, 49).”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799 · cited 1×
“Adenosine monophosphate-dependent kinase (AMPK) is a sensor of cellular energy status working as a cellular “fuel gauge” (8).”
BackgroundLeptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase
Minokoshi, Y., Kim, Y.-B., Peroni, O. D., Fryer, L. G. D., Müller, C., Carling, D., & Kahn, B. B. (2002) · Nature · doi:10.1038/415339a · Cited by 2,053
The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“The ability of metformin to lower blood glucose requires LKB1 and AMPK signals (48, 49).”
BackgroundAMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus
Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.-B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., et al. (2004) · Nature · doi:10.1038/nature02440 · Cited by 1,637
Chronic stress and obesity: a new view of “comfort food”
Dallman, M. F., Pecoraro, N., Akana, S. F., la Fleur, S. E., Gomez, F., Houshyar, H., Bell, M. E., Bhatnagar, S., Laugero, K. D., & Manalo, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934666100 · Cited by 1,369 · cited 3×
“(16, 17), 30% sucrose is added to the diet of”
BackgroundMethodDiagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362 · cited 1×
“The chronic high levels of glucocorticoid induce central obesity, systemic arterial hypertension, impaired glucose tolerance, fatty liver, and dyslipidemia (in addition to adverse effects on the gastric mucosa, bone and mood), ultimately leading to a clinical condition which, to a certain extent, resembles the metabol…”
BackgroundSelf-citationChronic stress at work and the metabolic syndrome: prospective study
Chandola, T., Brunner, E., & Marmot, M. (2006) · BMJ · doi:10.1136/bmj.38693.435301.80 · Cited by 1,075 · cited 2×
“Corticosteroids provide the link between stress, the metabolic syndrome, and mortality (27) and may also”
BackgroundDoes central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“Glucocorticoid effects on adipose cell differentiation and lipid accumulation are more pronounced in visceral than in subcutaneous fat, suggesting that glucocorticoids may play a pivotal role in the pathogenesis of central obesity (28).”
Background
Cited by
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349
Self-citationAMPK and SIRT1: a long-standing partnership?
Ruderman, N. B., Julia Xu, X., Nelson, L., Cacicedo, J. M., Saha, A. K., Lan, F., & Ido, Y. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00745.2009 · Cited by 903
AMPK, insulin resistance, and the metabolic syndrome
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67227 · Cited by 873
Begriche, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., & Fromenty, B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.006 · Cited by 555
AMPK: a metabolic gauge regulating whole-body energy homeostasis
Lage, R., Diéguez, C., Vidal-Puig, A., & López, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.007 · Cited by 505
Viollet, B., Guigas, B., Leclerc, J., Hébrard, S., Lantier, L., Mounier, R., Andreelli, F., & Foretz, M. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2009.01970.x · Cited by 486
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Animal models of metabolic syndrome: a review
Wong, S. K., Chin, K.-Y., Suhaimi, F. H., Fairus, A., & Ima-Nirwana, S. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0123-9 · Cited by 371
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 322
AMPK as a mediator of hormonal signalling
Lim, C. T., Kola, B., & Korbonits, M. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-09-0063 · Cited by 298
Self-citationMolecular Mechanisms of Glucocorticoid-Induced Insulin Resistance
Beaupere, C., Liboz, A., Fève, B., Blondeau, B., & Guillemain, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020623 · Cited by 271
Karatsoreos, I. N., Bhagat, S. M., Bowles, N. P., Weil, Z. M., Pfaff, D. W., & McEwen, B. S. (2010) · Endocrinology · doi:10.1210/en.2009-1436 · Cited by 260
“This result is in agreement with recent findings in an adrenalectomized and CORT pellet-treated rat model, where elevated WAT, plasma insulin, and plasma leptin were found, but with no concomitant body weight increase reported (18).”
ResultRafacho, A., Ortsäter, H., Nadal, A., & Quesada, I. (2014) · Journal of Endocrinology · doi:10.1530/joe-14-0373 · Cited by 216
Regulation of Lipogenesis by Glucocorticoids and Insulin in Human Adipose Tissue
Gathercole, L. L., Morgan, S. A., Bujalska, I. J., Hauton, D., Stewart, P. M., & Tomlinson, J. W. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026223 · Cited by 150
Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management
Scaroni, C., Zilio, M., Foti, M., & Boscaro, M. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1105 · Cited by 140
Self-citationRegulation of longevity by FGF21: interaction between energy metabolism and stress responses
Salminen, A., Kaarniranta, K., & Kauppinen, A. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.004 · Cited by 121
Warne, J. P. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.09.036 · Cited by 112
β-cell adaptation in a mouse model of glucocorticoid-induced metabolic syndrome
Fransson, L., Franzén, S., Rosengren, V., Wolbert, P., Sjöholm, Å., & Ortsäter, H. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0189 · Cited by 59
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Use of metformin in the treatment of polycystic ovary syndrome
Genazzani, A. D., Ricchieri, F., & Lanzoni, C. (2010) · Women's Health · doi:10.2217/whe.10.43 · Cited by 51
Metadata
- Authors
- Christ‐Crain, M., Kola, B., Lolli, F., Fekete, C., Seboek, D., Wittmann, G., Feltrin, D., Igreja, S. C., Ajodha, S., Harvey‐White, J., Kunos, G., Muller, B., Pralong, F., Aubert, G., Arnaldi, G., Giacchetti, G., Boscaro, M., B. Grossman, A., & Korbonits, M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2008-01-15
- Volume
- 22
- Issue
- 6
- Pages
- 1672-1683
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2160065587
- Cited by
- 170
- References
- 21
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.